Rivaroxaban to prevent clots in cancer patients with new catheters
Treatments studied
Part of Cancer, Heart & circulation clinical trials.
This Phase 3 study tests whether the medicine rivaroxaban can prevent dangerous blood clots in people with cancer who have a central venous catheter placed recently. It may help reduce clot risk while your catheter is in place, but you must meet safety and bleeding-risk criteria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 or older and have a new or existing cancer diagnosis
- You had a central venous catheter (CVC) placed within the last 72 hours
- Your CVC has not already been in place for more than 72 hours
- You are not already required to take blood thinners (anticoagulation) for another reason
- You have not had major bleeding in the last 4 weeks, and you do not have very high bleeding risk conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether rivaroxaban, a blood thinner pill, can help prevent dangerous blood clots in people with certain genitourinary cancers who are starting cancer treatment. It may lower clot risk, but it also has bleeding-risk tradeoffs that the study will monitor closely.
This trial tests whether a daily pill called edoxaban can prevent blood clots that sometimes form around a central venous catheter in people with cancer. If it works, it could lower the risk of a dangerous clot without major side effects.
This trial tests whether continuing a lower dose of blood thinners can prevent another blood clot in cancer patients who have had a clot in an arm or chest catheter. It may help find a safer way to prevent future clots.
This study tests a plan for how cancer patients taking blood thinners (called DOACs) should handle their medication before and after getting a central line (a special IV tube placed in a large vein for treatments). The goal is to find a safe way to prepare for the procedure without increasing the risk of bleeding or blood clots.
This study compares two blood-thinning medications, edoxaban and apixaban, in people who have both cancer and a blood clot. The goal is to see which one works better and is safer for preventing another clot while treating your cancer.
This study looks at how well blood thinners (anticoagulants) work in people with cancer who have had a blood clot. It aims to compare the benefits and risks of different anticoagulant medicines.
Hear when a new Venous Thromboembolism trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.